Human epidermal growth factor receptor 2 (HER2) is frequently overexpressed in human ovarian cancers and its overexpression is associated with increased angiogenesis, increased metastasis and reduced survival. Inhibition of HER2 in HER2-overexpressing cancers can lead to reduced angiogenesis and improved survival. Previously, we reported that SV40 T/t-common polypeptide has transcriptional repression activity and can inhibit HER2 expression. In this study, we investigated the effect of T/t-common on the angiogenesis-inducing activity of HER2-overexpressing human SK-OV-3 ovarian cancer cells. We found that compared to conditioned medium from control SK-OV-3 cancer cells, conditioned medium from T/t-common-expressing SK-OV-3 cells had a reduced ability to induce endothelial cell migration and tube formation in vitro and microvessel formation in vivo. These data indicate that T/t-common can inhibit the ability of SK-OV-3 cancer cells to induce angiogenesis. T/t-common was found to be able to downregulate the expression of several proangiogenic factors, including vascular endothelial growth factor-A, interleukin-8, basic fibroblast growth factor, matrix metalloproteinase-2 and urokinase-type plasminogen activator, and upregulate antiangiogenic factors, including thrombospondin-1 and tissue inhibitor of metalloproteinases-1 in SK-OV-3 cancer cells. Finally, we demonstrated that T/t-common could inhibit the angiogenesis and growth of HER2-overexpressing human ovarian tumor in NOD/SCID mice. Taken together, the data suggest that T/t-common had the potential to be developed as a new antiangiogenic agent specific for treating HER2-overexpressing ovarian cancers.
Introduction
Human epidermal growth factor receptor 2 (HER2, also called ErbB-2 or Neu) is a member of the class I receptor tyrosine kinase family, which also includes the epidermal growth factor receptor (or HER1), HER3 and HER4. 1, 2 HER2 is a unique member of the HER family in that it does not bind any of the known ligands with high affinity, but it is the preferred heterodimeric partner for other HER receptors. 2, 3 Through heterodimerization with other HER receptors, HER2 provides potent mitogenic, angiogenic, metastatic and antiapoptotic signals. [1] [2] [3] Amplification or overexpression of HER2 has been frequently detected in many types of human cancers, most notably breast and ovarian cancers. 4, 5 HER2 overexpression can lead to the formation of HER2:HER2 homodimer, which may transduce oncogenic signal in the absence of specific ligands. 1, 6 Alternatively, overexpressed HER2 may promote tumor formation as a result of spontaneous or ligand-induced heterodimerization with other HER receptors, notably HER3. 2, 7 Preclinical data show that HER2 activation contributes more to the oncogenic phenotype than any of the other HER receptors. 3, 8 In fact, overexpression of HER2 has been shown to be correlated with poor prognosis, 4, 5 increased angiogenesis, 5, 9 enhanced metastatic potential 5, 10 and increased chemoresistance of human cancers. 5, 11 Angiogenesis is the formation of new blood vessels from existent microvessels and is required for physiological and pathological processes. In physiological conditions such as organ growth/development, reproduction and wound healing, the delicate balance between pro-and antiangiogenic factors is tightly controlled. However, in pathological diseases like cancer, the perfect balance is disrupted. 12 The dysregulation of pro-and antiangiogenic factors in cancer cells can lead to angiogenesis, which is essential for tumor growth and metastasis. 13 One of the most potent proangiogenic factors is vascular endothelial growth factor-A (VEGF-A). VEGF-A binds to its cognate receptor on endothelial cells and causes these cells to proliferate, migrate and sprout new vessels.
14 VEGF-A expression in human cancers is correlated with increased microvessel density, increased metastasis and reduced survival. 15, 16 Overexpression of HER2 can upregulate VEGF-A expression. 17 This HER2-induced upregulation of VEGF-A has been postulated to be mediated through the transcription factor hypoxia-inducible factor-1a (HIF-1a). 18 Thrombospondin-1 (TSP-1) is a potent antiangiogenic factor that can bind directly to the CD36 receptor on the surface of endothelial cells. 19 TSP-1 can suppress angiogenesis by inhibiting endothelial cell proliferation, migration and tube formation, and by inducing endothelial cell apoptosis. 19, 20 It has been reported that overexpression of TSP-1 can inhibit tumor angiogenesis, resulting in the inhibition of tumor growth and metastasis. 21 On the contrary, low expression of TSP-1 is associated with increased recurrence rates and shorter survival in human cancers. Previous studies has shown that overexpression of HER2 can cause decreased expression of TSP-1 and that inhibition of HER2 with herceptin can activate p38 mitogen-activated protein kinase (p38 MAPK), resulting in increased expression of TSP-1. 9 Ovarian cancer is the leading cause of death from gynecological malignancies among women globally. Despite many efforts that have been made to cure ovarian cancer, long-term survival rates of patients remain low. HER2 is frequently overexpressed in ovarian cancers and its overexpression is associated with poor prognosis. 22, 23 A number of attempts have been made to inhibit HER2 expression or activity as a therapeutic approach for HER2-overexpressing ovarian cancers. However, clinical trials using these approaches have shown only modest benefit. 22, 24, 25 Therefore, the development of novel agents is urgently needed to improve the outcome of this disease.
Overexpression of HER2 can result in increased angiogenesis, 9, 26 and conversely, inhibition of HER2 can lead to decreased angiogenesis and reduced tumor growth in HER2-overexpressing cancers.
9,27,28 Previously, we reported that SV40 T/t-common polypeptide, which contains the Nterminal common domain of SV40 large T and small t antigens, has transcriptional repression activity 29 and can specifically inhibit HER2 expression in the HER2-overexpressing ovarian carcinoma cells. 30 These results suggest that T/t-common might have the ability to inhibit angiogenesis and tumor growth in HER2-overexpressing ovarian cancer. Here we report that T/t-common can inhibit the ability of HER2-overexpressing human ovarian cancer cells to induce angiogenesis. We also found that T/t-common could inhibit the angiogenesis and growth of HER2-overexpressing human ovarian tumor in NOD/SCID mice.
Materials and methods

Cell lines and culture
The HER2-overexpressing human ovarian carcinoma cell line SK-OV-3 was obtained from American Type Culture Collection (ATCC, Manassas, VA) and grown in Dulbecco's minimum essential medium/F12 medium (Hyclone, Logan, UT) supplemented with 10% fetal bovine serum (FBS; Gibco BRL, Gaithersburg, MD) in 5% CO 2 . The HER2 low-expressing human ovarian cancer cell line OVCAR-3 was obtained from ATCC and grown in RPMI 1640 medium (Hyclone) supplemented with 20% FBS and 10 mg ml À1 insulin in 5% CO 2 . The human microvascular endothelial cell line-1 (HMEC-1, obtained from Centers for Disease Control and Prevention, Atlanta, GA) was grown in MCDB131 medium (Gibco) supplemented with 10% FBS, 10 ng ml À1 epidermal growth factor (Becton Dickinson, San Jose, CA) and 1 mg ml À1 hydrocortisone (Sigma-Aldrich, St Louis, MO) in 5% CO 2 .
Adenoviral constructs
The recombinant adenovirus expressing the T/t-common polypeptide, rAd-T/t and the control vector adenovirus expressing only the green fluorescence protein, rAd-V, were described previously. 31 Preparation of concentrated conditioned medium In total, 3 Â 10 6 cells (SK-OV-3 or OVCAR-3) were infected with either rAd-V or rAd-T/t at appropriate multiplicity of infection, such that 490% of the cells were infected. The infected cells were incubated in medium containing 10% FBS for 24 h. The infected cells were then washed at least 10 times with phosphate-buffered saline (PBS) to remove uninfected viruses and incubated in serum-free medium. After 48 h, the medium was collected, filtrated to remove cell debris, and then concentrated 80-or 640-fold by centrifugation using Amicon Ultra-15 Centrifugal Filter Units (Millipore, Billerica, MA). The concentrated CM was stored at À80 1C. It should be noted that rAd-V-and rAd-T/t-infected SK-OV-3 cells grew as well as mock-infected SK-OV-3 cells under the culture condition used in this study (Supplementary Figure S1 ). No sign of cytotoxicity was observed in rAd-T/t-infected SK-OV-3 cells under the culture condition used here. Therefore, the effect of T/t-common on the angiogenesis-inducing activity of SK-OV-3 cells is not due to the toxic effect of T/t-common.
Western bolt and enzyme-linked immunosorbent assay Western blot analyses were carried out as described previously. 32 Equal amounts of extract protein were used in the analysis with appropriate antibodies. The antibodies used here are described in Supplementary Materials and methods. The levels of human VEGF-A in the supernatants were quantified by using human VEGF-A Enzyme-Linked Immunosorbent Assay Development System kit (R&D Systems, Minneapolis, MN).
RNA extraction, cDNA synthesis, semiquantitative reverse transcription-polymerase chain reaction and quantitative RT-PCR Total cellular RNA was extracted from cells using the TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. The concentration of RNA was quantified using the NanoDrop ND-1000 Spectrophotometer (Nano-Drop Technologies, Wilmington, DE). The RNA was treated with RNase-free DNase (Invitrogen) before doing reverse transcription (RT) to avoid the contamination of DNA. cDNA was synthesized using 1 mg of total RNA as the template and oligo-dT as a primer, as described in the manufacturer's protocol for RT (Invitrogen). For semiquantitative RT-polymerase chain reaction (RT-PCR), 0.05 mg cDNA was PCR amplified using primer pairs (see Supplementary Table  S1 ) specific for glyceraldehyde-3-phosphate-dehydrogenase (20 Supplementary Table  S1 ) in real-time PCR reaction. Amplification of the target sequences were detected with an ABI 7500HT sequence detection system (Applied Biosystems) and analyzed with the SDS 2.0 software (Applied Biosystems). The expression level of glyceraldehyde-3-phosphate-dehydrogenase was used to normalize the abundance of the test transcripts.
Cell transmigration assay
The in vitro cell migration assay was performed as described, 33 by using a 24-well Transwell Boyden Chamber (Millipore). The HMEC-1 endothelial cells (1 Â 10 5 ) suspended in 200 ml serum-free MCDB131 medium were seeded onto the upper compartment of the transwell chamber. The lower chamber was filled with serum-free MCDB131 medium containing 80-fold concentrated CM (60 ml) from mock-, rAd-V-or rAd-T/ t-infected SK-OV-3 or OVCAR-3 cells. After incubation for 20 h, the cells migrated to the lower chamber were fixed and stained as described. 33 The migrated cells were visualized and counted from six randomly selected fields ( Â 200 magnification) under an inverted microscope.
Tube formation assay
Tube formation of HMEC-1 endothelial cells on Matrigel was performed as described. 33 Matrigel (200 ml) was added to 24-well plates and allowed to solidify for 30 min at 37 1C. HMEC-1 cells (5 Â 10 4 cells per well) suspended in MCDB131 medium (final total volume ¼ 1 ml) containing 0.5% FBS (or 10% FBS) plus various volumes of concentrated CM from mock-, rAd-V-or rAd-T/t-infected SK-OV-3 (or OVCAR-3) cells were seeded on the solidified Matrigel. After incubation for 20 h, cells were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet in 20% methanol. Randomly chosen fields were photographed and the closed networks of vessel-like tubes were counted from six randomly selected fields.
Mouse Matrigel plug assay
Female NOD/SCID mice (6-8 weeks old) were purchased from Laboratory Animal Center at College of Medicine, National Taiwan University (Taipei, Taiwan) and housed in pathogen-free condition. The mice were subcutaneously injected with 500 ml of Matrigel containing 25 ml of 640-fold concentrated CM from mock-, rAd-V-or rAd-T/t-infected SK-OV-3 cells and heparin (10 U). After 7 days, mice were killed and Matrigel plugs were removed and photographed. To quantitate the formation of functional blood vessel, the amount of hemoglobin was measured using the Drakin's reagent kit (Sigma-Aldrich). All animal experiments in this study were performed following the Guidelines for Animal Experiments in National Taiwan University and were approved by the Institutional Animal Care and Use Committee in College of Medicine, National Taiwan University.
Human SK-OV-3 ovarian cancer xenograft model Female NOD/SCID mice (6-8 weeks old) were purchased from Laboratory Animal Center at College of Medicine, National Taiwan University and housed in pathogen-free condition throughout the experimental duration. SK-OV-3 cancer cells (2 Â 10 6 cells suspended in 100 ml of PBS) were injected subcutaneously into both flanks of the mouse. At 1 week after tumor cell inoculation, the mice were randomly divided into three groups. The weight of the mice in these three groups was similar at this time point. Group 1 mice were injected intratumorally with 100 ml of PBS; group 2 mice were injected intratumorally with PBS containing 3 Â 10 8 PFU of rAd-V; and group 3 mice were injected intratumorally with PBS containing 3 Â 10 8 PFU of rAd-T/t. The injection was repeated at 3-or 4-day intervals until each mouse received a total of four injections. The mouse tumor size was measured at different time points following first-agent treatment, and the tumor volume was calculated according to the following formula: 1/2 (length Â width 2 ). The tumors were removed at day 70 after tumor implantation and photographed. The tumors were snap-frozen in liquid nitrogen for immunohistochemical and TdT-mediated dUTP nick-end labeling (TUNEL) analyses.
Immunohistochemical and TUNEL analyses
Cryostat sections of frozen tumors were fixed with 4% paraformaldehyde, washed with PBS and the endogenous peroxidase activity was blocked with Dako Dual endogenous enzyme block (Dako, Glostrup, Denmark). After washing with PBS, the sections were blocked with 5% FBS in PBS. To detect CD31-positive stained microvessels, the sections were probed with rat anti-CD31 antibody (Becton Dickinson), and then incubated with horseradish peroxidase-conjugated secondary antibody by using Rat on Mouse HRP-Polymer Kit (Biocare Medical, Concord, CA). Following color development by using Dako DAB reagent (Dako), the nuclei were stained with hematoxylin. The sections were then sealed with glycerol gelatin (Sigma-Aldrich) for microscopic observation. Randomly chosen fields were photographed at Â 400 magnification and the number of CD31-positive stained blood vessels was counted. For TUNEL assay, the cryostat sections were fixed in 4% paraformaldehyde, washed with PBS and permeated with permeabilization solution (0.1% Triton X-100, 0.1% sodium citrate in PBS). The sections were then labeled with TUNEL reaction mixture according to the protocol provided by the manufacturer (Roche Applied Science, Mannheim, Germany) to detect apoptotic cells. Following TUNEL reaction, the sections were rinsed three times with PBS and incubated in Hoechst 33258 solution to label nuclear DNA. The sections were then sealed with mounting medium (Sigma-Aldrich) and subjected to fluorescence microscopy. Randomly chosen fields were photographed at Â 200 magnification and the number of TUNELpositive cells was counted.
Statistical analyses
Data are present as the mean±s.d. The significance of the difference between groups was evaluated with the Student's t-test; Po0.05 was considered significant.
Results
The ability of HER2-overexpressing SK-OV-3 ovarian cancer cells to induce angiogenesis is inhibited by T/t-common To investigate whether T/t-common could inhibit the ability of SK-OV-3 cells to induce angiogenesis, we first tested whether conditioned medium (CM) from T/t-common-expressing SK-OV-3 cells had lower ability to induce endothelial cell migration than CM from non-T/t-common-expressing SK-OV-3 cells. SK-OV-3 cells were mock-infected or infected with either a recombinant adenovirus carrying the T/t-common gene (rAd-T/t) or a vector adenovirus (rAd-V). rAd-T/t infection of SK-OV-3 cells could produce a significant amount of T/t-common protein, whereas rAd-V could not. 31 Moreover, rAd-T/t infection could inhibit HER2 expression and HER2 phosphorylation (that is, HER2 activity) in SK-OV-3 cells (Figure 1a) . The infected cells were cultured in serum-free medium for 48 h and the CM was collected. The CM was then used as a chemoattractant to induce the migration of HMEC-1 endothelial cells in the Boyden chamber transwell assay. As shown in Figure 1b , CM from rAd-T/t-infected SK-OV-3 cells had much lower ability to induce HMEC-1 migration than CM from mock-or rAd-V-infected SK-OV-3 cells. These data indicate that T/t-common can inhibit the ability of SK-OV-3 cells to induce endothelial cell migration. We also tested whether T/t-common could inhibit the ability of HER2 low-expressing OVCAR-3 ovarian cancer cells to induce endothelial cell migration in the similar assay as described above. The OVCAR-3 cells produced much lower amount of HER2 protein than the SK-OV-3 cells did (Supplementary Figure S2) . As shown in Figure 1c , CM from rAd-T/t-infected OVCAR-3 cells had slightly higher ability to induce HMEC-1 migration than CM from mock-or rAd-V-infected OVCAR-3 cells, suggesting that T/t-common cannot inhibit the ability of HER2 low-expressing ovarian cancer cells to induce endothelial cell migration.
We then tested whether T/t-common could inhibit the ability of HER2-overexpressing SK-OV-3 cells to induce endothelial cell tube formation. To do this, HMEC1 endothelial cells were incubated in the low-serum medium (with 0.5% FBS) containing either no CM or CM from mock-, rAd-V-or rAd-T/t-infected SK-OV-3 cells. As shown in Figure 2a , HMEC-1 cells had low ability to form tubes in the low-serum medium. CM from mock-or rAd-V-infected SK-OV-3 cells could enhance tube formation by HMEC-1 cells. In contrast, CM from rAd-T/t-infected cells could inhibit rather than enhance the ability of HMEC-1 to form tubes. These data suggest that CM from rAd-T/t-infected SK-OV-3 cells not only had lower concentration of proangiogenic factors, but also had higher concentration of antiangiogenic factors than CM from mock-or rAd-V-infected SK-OV-3 cells. To validate this, the ability of HMEC-1 to form tube was tested in high-serum medium (with 10% FBS) containing increasing concentrations of CM from mock-, rAd-V-or rAd-T/t-infected SK-OV-3 cells. As shown in Figure 2b , while CM from mock-or rAd-V-infected SK-OV-3 cells did not affect HMEC-1 tube formation, CM from rAd-T/t-infected SK-OV-3 cells could inhibit HMEC-1 tube formation in a dose-dependent manner. We also tested whether CM from rAd-T/t-infected HER2 lowexpressing OVCAR-3 ovarian cancer cells could inhibit HMEC-1 tube formation in high-serum medium. As shown in Figure 2c , the ability of HMEC-1 to form tubes was not affected by CM from rAd-T/t-infected OVCAR-3 cells, suggesting that T/t-common may not inhibit the ability of HER2 low-expressing ovarian cancer cells to induce endothelial cell tube formation.
To investigate whether T/t-common could inhibit the ability of SK-OV-3 cancer cells to induce vascularization in vivo, the Matrigel plug assay was performed. As shown in Figure 3a , Matrigel plugs containing CM from rAd-T/t-infected SK-OV-3 cells exhibited lighter red color than plugs containing CM from mock-or rAd-V-infected SK-OV-3 cells. The extent of angiogenesis was quantified by measuring the hemoglobin content in the plugs. The amount of hemoglobin in the Matrigel plugs containing CM from rAd-T/t-infected SK-OV-3 cells was significantly lower than that in the plugs containing CM from mock-or rAd-V-infected SK-OV-3 cells (Figure 3b) , suggesting that T/t-common can inhibit the ability of HER2-overexpressing SK-OV-3 cancer cells to induce blood vessel formation in vivo.
Modulation of pro-and antiangiogenic factors by T/t-common in HER2-overexpressing SK-OV-3 cancer cells To study the mechanism by which T/t-common inhibits the angiogenesis-inducing activity of SK-OV-3 cancer cells, the expression level of pro-and antiangiogenic factors in rAd-T/t-and rAd-V-infected SK-OV-3 cells were measured by quantitative RT-PCR. Our data indicated that while the expression of several proangiogenic factors, including VEGF-A, interleukin-8 (IL-8), basic fibroblast growth factor, matrix metalloproteinase-2 and urokinase-type plasminogen activator, was downregulated, that of antiangiogenic factors, TSP-1 and tissue inhibitor of metalloproteinases-1(TIMP-1), was upregulated by T/t-common in SK-OV-3 cells (Figure 4 ). Whereas the expression of VEGF-A was inhibited about 2.4-fold, that of TSP-1 was upregulated about 2.5-fold by T/t-common in SK-OV-3 cells.
To Figure 5a , the expression level of both VEGF-A mRNA and VEGF-A protein was lower in rAd-T/t-infected SK-OV-3 cells than in mock-or rAd-V-infected SK-OV-3 cells. The amount of VEGF-A secreted into the medium was also measured by enzyme-linked immunosorbent assay. As shown in Figure 5b , the amount of VEGF-A secreted by rAd-T/t-infected SK-OV-3 cells was lower than that secreted by mock-or rAd-V-infected SK-OV-3 cells under both normoxic-and hypoxia-like conditions. Taken together, these data demonstrate that T/t-common can downregulate VEGF-A expression in SK-OV-3 cells.
confirm that the expression of VEGF-A is inhibited by T/t-common in SK-OV-3 cells, the expression level of VEGF-A mRNA and VEGF-A protein in mock-, rAd-V-and rAd-T/t-infected SK-OV-3 cells under normoxic conditions was measured by semiquantitative RT-PCR and western blot, respectively. As shown in
The upregulation of VEGF-A expression in HER2-overexpressing cells has been shown to be mediated through the transcription factor HIF-1a.
18, 34 We thus tested whether T/t-common could inhibit HIF-1a expression in SK-OV-3 cells. As shown in Figure 5c , the expression of HIF-1b protein was similar in mock-, rAd-V-and rAd-T/t-infected SK-OV-3 cells, whereas that of HIF-1a protein was downregulated in rAd-T/t-infected SK-OV-3 cells. These data indicate that T/t-common can specifically inhibit HIF-1a expression in SK-OV-3 cells. Overexpression of HER2 triggers the activation of the phosphatidylinositol-3-kinase-AKT and MEK-ERK pathways, which in turn stimulates the expression of HIF-1a and VEGF-A. 18, 34, 35 To test which pathway is involved in T/t-common-mediated inhibition of HIF-1a and VEGF-A expression in SK-OV-3 cells, we measured the activities of ERK and AKT in rAd-V-and rAd-T/ t-infected SK-OV-3 cells by using antibodies against phospho-ERK1/2 and phospho-AKT. As shown in Figure 5d , whereas the level of phospho-ERK1/2 was significantly lower in rAd-T/t-infected cells than in rAd-V-infected cells, the level of phospho-AKT was similar in rAd-T/t-and rAd-V-infected cells. Moreover, the levels of total ERK1/2 and AKT proteins were similar in rAd-V-and rAd-T/t-infected cells. Taken together, these data 
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indicate that T/t-common can inhibit the activity of ERK1/2 in SK-OV-3 cells. Therefore, T/t-common may repress HIF-1a and VEGF-A expression through inhibiting the MEK-ERK pathway in SK-OV-3 cells.
To confirm that the expression of TSP-1 is upregulated by T/t-common in SK-OV-3 cells, the expression level of TSP-1 mRNA and TSP-1 protein in mock-, rAd-V-and rAd-T/t-infected SK-OV-3 cells was measured by semiquantitative RT-PCR and western blot, respectively. The expression level of both TSP-1 mRNA and TSP-1 protein was higher in rAd-T/t-infected SK-OV-3 cells than in mock-or rAd-V-infected SK-OV-3 cells (Figure 5e ), indicating that T/t-common can upregulate TSP-1 expression in SK-OV-3 cells. It has been reported that inhibition of HER2 can activate p38 MAPK, which in turn stimulates TSP-1 expression. 9 Because T/t-common can inhibit HER2, we thus tested whether T/t-common could stimulate the activity of p38 MAPK in SK-OV-3 cells. As shown in Figure 5f , compared with mock-or rAd-V-infected SK-OV-3 cells, the level of phospho-p38 was significantly increased in rAd-T/t-infected SK-OV-3 cells, and the level of total p38 protein was not altered in these cells. These data indicate that T/t-common indeed can activate p38 MAPK in SK-OV-3 cells. To study whether T/t-common upregulation of TSP-1 was mediated through p38 MAPK, inhibitor of p38 MAPK (SB203580) was added to the culture medium following virus infection. As shown in Figure 5g , the upregulation of TSP-1 expression was blocked by the p38 MAPK inhibitor in rAd-T/t-infected SK-OV-3 cells, suggesting that T/t-common upregulation of TSP-1 is mediated through the p38 MAPK pathway in SK-OV-3 cells.
T/t-common inhibits tumor angiogenesis and tumor growth in HER2-overexpressing SK-OV-3 ovarian cancer xenografts in NOD/SCID mice
The preceding data prompted us to assess the antitumor and antiangiogenic activity of T/t-common in vivo. Female NOD/SCID mice were subcutaneously injected with 2 Â 10 6 SK-OV-3 ovarian cancer cells. After 1 week, mice were randomly divided into three groups: group 1 was intratumorally injected with PBS; group 2 was intratumorally injected with rAd-V virus; and group 3 was intratumorally injected with rAd-T/t virus. The tumor size was measured at different time points following PBS or virus treatment. As shown in Figure 6a , the growth of the tumors was slower in rAd-T/t-treated mice than in PBS-or rAd-V-treated mice, indicating that T/t-common can inhibit the growth of SK-OV-3 tumors. The tumors were removed and the immunohistochemical staining of CD31-positive microvessels on tumor sections were performed. As shown in Figure 6b , tumors from rAd-T/t-treated mice contained fewer CD31-positive microvessels than tumors from PBSor rAd-V-treated mice, indicating that T/t-common can inhibit angiogenesis in HER2-overexpressing SK-OV-3 tumors. The TUNEL assay on tumor sections revealed that tumors from rAd-T/t-treated mice contained much more apoptotic cells than those from rAd-V-treated mice (Figure 6c ), indicating that T/t-common can induce the apoptosis of HER2-overexpressing SK-OV-3 tumors.
Discussion
Ovarian cancer is the major cause of morbidity and mortality in women. Previous studies have shown that -1a) was downregulated in rAd-T/t-infected SK-OV-3 cells under both normoxicand hypoxia-like conditions. SK-OV-3 cells were treated as described in (b) and cell lysates were then subjected to western blot analysis using antibodies against HIF-1a and HIF-1b. (d) The activity of ERK1/2 was downregulated in rAd-T/t-infected SK-OV-3 cells. rAd-V-or rAd-T/t-infected SK-OV-3 cells were incubated in serum-free medium for 48 h. Cell lysates were then subjected to western blot analysis using antibodies against phospho-ERK1/2 and phospho-AKT. The same blot was reprobed with antibodies against ERK1/2 and AKT. (e) Expression of TSP-1 was upregulated in rAd-T/t-infected SK-OV-3 cells. Mock-, rAd-V-or rAd-T/t-infected SK-OV-3 cells were incubated in serum-free medium for 48 h. The level of TSP-1 mRNA and TSP-1 protein in cell extracts was analyzed by semiquantitative RT-PCR (upper panel) and western blot (lower panel), respectively. (f) The activity of p38 was upregulated in rAd-T/t-infected SK-OV-3 cells. Mock-, rAd-V-or rAd-T/t-infected SK-OV-3 cells were incubated in serum-free medium for 48 h. Cell lysates were then subjected to western blot analysis using antibodies against phospho-p38. The same blot was reprobed with antibodies against p38. (g) The upregulation of TSP-1 expression was blocked by the p38 inhibitor in rAd-T/ t-infected SK-OV-3 cells. Mock-, rAd-V-or rAd-T/t-infected SK-OV-3 cells were incubated in serum-free medium with or without 10 mM SB203580, a p38 inhibitor, for 24 h. The level of TSP-1 mRNA in cell extracts was then analyzed by semiquantitative RT-PCR.
increased angiogenesis is associated with poor prognosis in ovarian cancer and that antiangiogenic treatments may be a promising strategy to treat ovarian cancer. 24, 36 In this study, we demonstrated that SV40 T/t-common polypeptide could inhibit the angiogenesis and growth of HER2-overexpressing SK-OV-3 ovarian tumors in NOD/SCID mice ( Figure 6 ). We also demonstrated that CM from T/tcommon-expressing HER2-overexpressing SK-OV-3 ovarian cancer cells had lower ability to induce endothelial cell migration and tube formation in vitro (Figures 1  and 2 ) and microvessel formation in vivo (Figure 3 ) than CM from control SK-OV-3 cells, indicating that T/t-common can inhibit the ability of SK-OV-3 cancer cells to induce angiogenesis. This activity of T/t-common may be derived from its ability to inhibit HER2 and to modulate the expression of several pro-and antiangiogenic factors in SK-OV-3 cancer cells (Figures 4 and 5) . The ability to target multiple targets in HER2-overexpressing ovarian cancer cells makes T/t-common a potential antiangiogenic agent for treating HER2-overexpressing ovarian cancers.
The ability of T/t-common to inhibit the angiogenesisinducing activity of SK-OV-3 cancer cells may be derived from its ability to repress HER2. This conclusion is supported by the following evidences. Firstly, re-expression of HER2 in T/t-common-expressing SK-OV-3 cells could more or less restore the activity of these cells to induce endothelial cell migration and tube formation (Supplementary Figure S3) . Secondly, T/t-common could modulate the expression of several pro-and antiangio- genic factors in SK-OV-3 cells (Figures 4 and 5) , and some of them (such as VEGF-A, IL-8, matrix metalloproteinase-2, urokinase-type plasminogen activator and TSP-1) have been shown to be the downstream targets of HER2. 9, 10, 28, 37, 38 Thirdly, T/t-common could reproduce some of the results (such as downregulation of VEGF-A and IL-8 and upregulation of TSP-1) obtained by expressing HER2 short interfering RNA in HER2-overexpressing cancer cells. 9, 27 Fourthly, T/t-common could inhibit the angiogenesis-inducing activity of the HER2-overexpressing SK-OV-3 ovarian cancer cells, but not that of the HER2 low-expressing OVCAR-3 ovarian cancer cells (Figures 1 and 2) . Fifthly, we have found that T/tcommon could inhibit the activity of HER2-overexpressing BT-474 breast cancer cells, but not that of HER2 low-expressing MDA-MB-231 breast cancer cells, to induce endothelial cell migration (Supplementary Figure S4) .
In addition to the ability to inhibit HER2, other activities of T/t-common may also contribute to its ability to inhibit the angiogenesis-inducing activity of SK-OV-3 cells. For instance, we have found that T/t-common could interact with the transcriptional co-activator p300 and inhibit the activity of the latter (data not shown). As p300 has been shown to be a transcriptional coactivator of HIF-1a and involved in the induction of angiogenesis, 39 it is possible that T/t-common's ability to interact with and inhibit p300 may also contribute to its ability to inhibit angiogenesis. In this respect, T/t-common may be more effective than herceptin, a humanized monoclonal antibody against HER2, in inhibiting angiogenesis. Further experiments comparing the antiangiogenic and antitumor activities of T/t-common and herceptin are needed to support this hypothesis.
We found that compared to rAd-V-infected SK-OV-3 cells, rAd-T/t-infected SK-OV-3 cells had reduced expression of several proangiogenic factors, including VEGF-A, IL-8, basic fibroblast growth factor, urokinasetype plasminogen activator and matrix metalloproteinase-2, and elevated the expression of antiangiogenic factors, including TSP-1 and TIMP-1 (Figures 4 and 5) . These data are consistent with the previous reports that VEGF-A, IL-8, urokinase-type plasminogen activator and matrix metalloproteinase-2 are upregulated, whereas TSP-1 is downregulated by HER2. 9, 10, 28, 37, 38 The ability to target multiple pro-and antiangiogenic factors in HER2-overexpressing cancer cells makes T/t-common a potentially better choice than single-target antiangiogenic agents, such as anti-VEGF antibody bevacizumab, for treating HER2-overexpressing cancers.
We found that T/t-common could inhibit the expression and secretion of VEGF-A in HER2-overexpressing SK-OV-3 cancer cells under both normoxic-and hypoxialike conditions (Figures 5a and b) . The ability of T/t-common to inhibit VEGF-A expression in SK-OV-3 cells may be derived from its ability to inhibit HER2-mediated ERK1/2 activity (Figure 5d ). Several activities of ERK1/2 have been shown to be involved in the upregulation of VEGF-A. Firstly, ERK1/2 can phosphorylate ribosomal protein S6 either directly or indirectly, [40] [41] [42] leading to translation of VEGF-A. 43 Secondly, ERK1/2 can phosphorylate the transcription factor Sp-1, leading to transcription of VEGF-A. 44, 45 Thirdly, ERK1/2 can phosphorylate HIF-1a, enhance the transcriptional activity of HIF-1a, leading to transcription of VEGF-A. 46, 47 Fourthly, ERK1/2 can stimulate the phosphorylation of the translational regulatory proteins 4E-BP1, p70S6 kinase and eIF-4E, causing increased synthesis of HIF-1a protein, leading to VEGF-A transcription. The ability of T/t-common to inhibit the phosphorylation of ERK1/2 (Figure 5d ) may cause the above activities of ERK to be inhibited, resulting in the downregulation of VEGF-A expression.
We found that CM from T/t-common-expressing SK-OV-3 cancer cells can inhibit serum-induced tube formation by endothelial cells (Figure 2b ). This result suggests that T/t-common can induce the expression of antiangiogenic factors in SK-OV-3 cancer cells. Indeed, we demonstrated that T/t-common can upregulate the expression of antiangiogenic factors, TSP-1 and TIMP-1, in SK-OV-3 cancer cells (Figures 4 and 5e ). The ability of T/t-common to induce, in cancer cells, the expression of antiangiogenic factors (such as TSP-1) that can be secreted to the surrounding environment is important for suppression of tumor angiogenesis in vivo (Figure 6 ), because even only part of cancer cells were infected by T/t-common-carrying virus, and the neovessel formation in the tumor can still be efficiently inhibited.
In this study, we demonstrated that T/t-common can inhibit the growth of HER2-overexpressing SK-OV-3 tumors in NOD/SCID mice (Figure 6a ). Although we cannot rule out the possibility that T/t-common inhibit the proliferation of SK-OV-3 tumor cells, we believe that the antiangiogenic and apoptosis-inducing activities of T/t-common contribute most to its inhibitory effect on SK-OV-3 tumors. Previously, T/t-common has been shown to be able to induce apoptosis of HER2-overexpressing cancer cells under stressed conditions, such as low-serum condition. 31 It is possible that T/t-common, through inhibition of angiogenesis, creates a low-serumlike condition that may facilitate T/t-common to induce apoptosis in HER2-overexpressing tumors. Indeed, we found that rAd-T/t-treated HER2-overexpressing SK-OV-3 tumors contained fewer microvessels (Figure 6b ) and underwent more severe apoptosis (Figure 6c ) than rAd-V-treated SK-OV-3 tumors. In addition to having the ability to induce apoptosis and inhibit angiogenesis, T/t-common was also found to be able to inhibit the migration ability of HER2-overexpressing cancer cells (Supplementary Figure S5) . Taken together, these data indicate that T/t-common has multiple antitumor activities and may have the potential to be developed into a therapeutic agent against HER2-overexpressing cancers.
